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Abstract 
Background: The use of novel sepsis biomarkers has increased in recent years. However, their prognostic value 
with respect to illness severity has not been explored. In this work, we examined the ability of mid‑regional proadre‑
nomedullin (MR‑proADM) in predicting mortality in sepsis patients with different degrees of organ failure, compared 
to that of procalcitonin, C‑reactive protein and lactate.
Methods: This was a two‑centre prospective observational cohort, enrolling severe sepsis or septic shock patients 
admitted to the ICU. Plasma biomarkers were measured during the first 12 h of admission. The association between 
biomarkers and 28‑day mortality was assessed by Cox regression analysis and Kaplan–Meier curves. Patients were 
divided into three groups as evaluated by the Sequential Organ Failure Assessment (SOFA) score. The accuracy of the 
biomarkers for mortality was determined by area under the receiver operating characteristic curve (AUROC) analysis.
Results: A total of 326 patients with severe sepsis (21.7%) or septic shock (79.3%) were enrolled with a 28‑day mortal‑
ity rate of 31.0%. Only MR‑proADM and lactate were associated with mortality in the multivariate analysis: hazard 
ratio 8.5 versus 3.4 (p < 0.001). MR‑proADM showed the best AUROC for mortality prediction at 28 days in the analysis 
over the entire cohort (AUROC [95% CI] 0.79 [0.74–0.84]) (p < 0.001). When patients were stratified by the degree of 
organ failure, MR‑proADM was the only biomarker to predict mortality in all severity groups (SOFA ≤ 6, SOFA = 7–12, 
and SOFA ≥ 13), AUROC [95% CI] of 0.75 [0.61–0.88], 0.74 [0.66–0.83] and 0.73 [0.59–0.86], respectively (p < 0.05). All 
patients with MR‑proADM concentrations ≤0.88 nmol/L survived up to 28 days. In patients with SOFA ≤ 6, the addi‑
tion of MR‑proADM to the SOFA score increased the ability of SOFA to identify non‑survivors, AUROC [95% CI] 0.70 
[0.58–0.82] and 0.77 [0.66–0.88], respectively (p < 0.05 for both).
Conclusions: The performance of prognostic biomarkers in sepsis is highly influenced by disease severity. MR‑
proADM accuracy to predict mortality is not affected by the degree of organ failure. Thus, it is a good candidate in the 
early identification of sepsis patients with moderate disease severity but at risk of mortality.
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Background
Sepsis remains the primary cause of death in inten-
sive care unit (ICU) patients despite improvements in 
antibiotic and early hemodynamic management. In 
Europe, sepsis occurrence in acutely ill patients results 
in an ICU mortality rate ranging between 27 and 54% 
depending on the severity [1]. In the USA, the Centre for 
Disease Control estimates that 500,000 people develop 
sepsis and 200,000 die each year [2, 3]. The prompt 
diagnosis and assessment of high risk sepsis patients is 
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therefore highly desirable, increasing the possibility of 
initiating early and specific treatments. Thus, clinical 
severity scores such as Sequential Organ Failure Assess-
ment (SOFA) score can play a critical role [4]. However, 
the isolated use of these scoring systems to guide deci-
sion-making in sepsis has been heavily criticized [5]. A 
standardized assessment tool for the early identification 
of sepsis patients upon admission with a range of sever-
ity levels would be of dramatic value in aiding clinical 
decision-making and optimizing the use of health care 
resources. Accordingly, a number of prognostic biomark-
ers have been proposed in the field of sepsis over the last 
decades—many more than in other diseases. Most of 
these molecules are hormones, cytokines or circulating 
proteins related to inflammation or the coagulation sys-
tem and may require considerable time, effort and costs 
to be measured [6].
Adrenomedullin (ADM) is a peptide which can act as 
a hormone and is produced by multiple tissues during 
physiologic and infectious stress with varying physiologi-
cal functions, including vasodilatory, anti-inflammatory 
and antimicrobial activity, which is further enhanced by 
its regulation and modulation of complement activity [7]. 
Thus, ADM is considered a “hormokine”, characterized 
by a hormone-like behaviour in non-inflammatory condi-
tions when it is only produced by endocrine cells, and by 
a cytokine-like behaviour in sepsis when it is ubiquitously 
hyper-expressed. Moreover, exogenous ADM has been 
shown to reduce acute lung injury, vascular permeability 
and death in animal models of sepsis, whilst endogenous 
over-expression similarly ameliorates the sepsis insult [8, 
9]. Measurement of circulating ADM is complicated by a 
rapid degradation and clearance from the circulation, and 
is further masked by a binding protein (complement fac-
tor H), preventing its detection by standard immunoassay. 
The mid-regional fragment of proadrenomedullin (MR-
proADM), comprising of amino acids 45–92, is more 
stable and directly reflects levels of the rapidly degraded 
active ADM peptide [10]. Increased MR-proADM con-
centrations have been identified in the plasma of patients 
with community acquired pneumonia (CAP) and are 
widely used in the risk and severity assessment of this 
condition [11–13]. However, very few are available for 
severe sepsis and septic shock patients. Additionally, the 
influence of disease severity on the performance of prog-
nostic biomarkers in sepsis has not been appropriately 
studied yet.
In this study, we aimed to evaluate the ability of MR-
proADM levels to predict 28-day mortality in sepsis 
patients, compared to other standard biomarkers (proc-
alcitonin (PCT), C-reactive protein (CRP), and lactate), 
in three different levels of disease severity as measured by 
the SOFA score.
Methods
Patient selection, inclusion and exclusion criteria
This study was a prospective observational cohort of 
patients recruited consecutively from two intensive care 
units (ICU) in Spain and France. Adult patients with age 
≥18 years and admitted to the ICU from April 2013 to 
January 2016 were enrolled within 12  h after meeting 
criteria for severe sepsis or septic shock, based on the 
SEPSIS-2 definition by the American College of Chest 
Physicians/Society of Critical Care Medicine Consensus 
Conference [14]. Enrolled patients also had SOFA score 
≥2 and therefore met criteria for the new SEPSIS-3 
definition for sepsis [15]. Patients with human immuno-
deficiency virus (HIV) infection and those undergoing 
radiotherapy or receiving immunosuppressive drugs, 
including chemotherapy or systemic steroids, in the 
3  months prior to admission to the ICU were consid-
ered to be immunosuppressed. Exclusion criteria were 
age <18  years, the presence of pregnancy, the absence 
of a blood sample available for biomarker profiling 
within the first 12  h following ICU admission, or lack 
of informed consent. Clinical data recorded from the 
medical records included demographics, comorbidities, 
laboratories, microbiology, and biomarker levels. The 
severity of illness was assessed on admission by calcu-
lating the Sequential Organ Failure Assessment (SOFA) 
score.
Biomarker evaluation
Plasma samples for biomarker profiling were collected 
as close as possible to the moment of ICU admission, 
and always within the first 12  h. Plasma MR-proADM 
measurement was performed by TRACE technology 
(Time Resolved Amplified Cryptate Emission) using a 
new sandwich immunoassay (Kryptor Compact Plus 
Analyser, BRAHMS, Hennigsdorf, Germany); limit of 
detection 0.05  nmol/L. PCT measurement was per-
formed by electrochemiluminescence immunoassay 
(ECLIA) on a chemistry analyser (Cobas 6000, Roche 
Diagnostics, Meylan, France); limit of detection 0.02 ng/
ml. Serum CRP and lactate were measured by particle-
enhanced immunoturbidimetric and colorimetric assay, 
respectively (e501 Module Analyser, Roche Diagnos-
tics, Meylan, France); limit of detection 0.15 mg/dL and 
0.2 mmol/L, respectively.
Statistical analysis
Differences in demographic and clinical characteristics 
between survivors and non-survivors were assessed using 
the Chi-square test for categorical variables. Student’s t 
test or Mann–Whitney U test were, respectively, used 
to compare continuous variables based upon the pres-
ence or absence of normal distribution. The association 
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between biomarkers and the risk of mortality was 
assessed by Cox regression analysis, adjusted by con-
founding variables. Time was censored at 28 days follow-
ing admission to the ICU. The first 24 h of ICU admission 
was considered as day 1 in the analysis. Variables yield-
ing a p < 0.05 in the univariate regression analysis were 
further included in the multivariate analysis. Biomark-
ers were log transformed in order to reach a normal dis-
tribution. The impact of biomarkers on mean survival 
time was assessed by using Kaplan–Meier curves and 
the Mantel–Haenszel log-rank test. Similar to the Cox 
regression analysis, time was censored at 28 days follow-
ing admission to the ICU. Accuracy and predictive val-
ues of the biomarkers for mortality were evaluated by 
calculating the area under the receiver operating char-
acteristic (AUROC) curve. Patients were distributed into 
three groups depending on disease severity as assessed 
by the SOFA score using two predefined cut-offs, one 
with a sensitivity close to 90% and the other showing a 
specificity close to 90% for detecting non-survivors at 
28 days (Additional file 1: Figure S1). Data were analysed 
by using the IBM SPSS 20.0 software (SPSS, Chicago, Ill).
Results
Patient characteristics and biomarker concentrations
Three hundred and twenty-six patients (326) with severe 
sepsis (21.7%) or septic shock (79.3%) were enrolled with 
a 28-day mortality rate of 25.5 and 34.9% in Valladolid 
and Dijon, respectively, and an overall mortality rate of 
31.0% across both sites (Table  1). The median age was 
65 years and 54.3% of patients were male. Compared to 
survivors, non-survivors were older and presented with 
higher SOFA scores, and an increased incidence of sep-
tic shock, mechanical ventilation, renal replacement 
therapy, neoplasia, cardiovascular disease, chronic renal 
failure, immunosuppression, and respiratory disease (all 
p < 0.05). The most common source of infection was of 
respiratory and urologic origin, regardless of outcome. 
Table 1 Clinical characteristics of the patients: data are presented as mean (S.D.) or median (IQR) where appropriate








Patients from Valladolid (n, %) 102 (45.3%) 35 (34.7%) 137 0.071
Patients from Dijon (n, %) 123 (54.7%) 66 (65.3%) 189
Male (n, %) 133 (59.1%) 68 (67.3%) 201 (61.4%) 0.098
Age (years) (mean, SD) 63 (14) 69 (12) 65.4 (14) <0.001
SOFA (mean, SD) 8 (3.4) 11 (3.5) 9 (3.7) <0.001
Septic shock (n, %) 152 (67.5%) 87 (86.1%) 239 (73.3%) 0.020
Mechanical ventilation (n, %) 150 (66.7%) 89 (88.1%) 239 (73.3%) <0.001
RRT (n, %) 40 (17.7%) 45 (44.6%) 85 (26.2%) <0.001
ICU stay (days) (mean, SD) 12.9 (18) 7.7 (6.7) 11.2 (15.6) 0.012
Neoplasia (n, %) 47 (21%) 35 (34.7%) 82 (25.2%) 0.007
Diabetes (n, %) 58 (25.8%) 29 (28.7%) 87 (26.7%) 0.330
COPD (n, %) 33 (14.7%) 16 (15.8%) 49 (15%) 0.450
Cardiovascular disease (n, %) 56 (25%) 41 (40.6%) 97 (29.8%) 0.030
Chronic renal failure (n, %) 16 (7.1%) 16 (15.8%) 32 (9.8%) 0.014
Immunosuppression (n, %) 21 (9.3%) 25 (24.8%) 46 (14.1%) <0.001
Respiratory infection (n, %) 98 (43.6%) 58 (57.4%) 156 (48%) 0.014
Urologic infection (n, %) 75 (33.3%) 36 (35.6%) 111 (34%) 0.380
Abdominal infection (n, %) 25 (11.1%) 10 (9.9%) 35 (10.7%) 0.450
Other infection (n, %) 32 (14%) 11 (10.9%) 43 (13%) 0.40
Primary or secondary bacteremia (n, %) 69 (30.7%) 38 (37.6%) 107 (32.8%) 0.130
Gram − bacteria (n, %) 62 (27.6%) 28 (27.7%) 90 (27.6%) 0.975
Gram + bacteria (n, %) 47 (20.9%) 22 (21.8%) 69 (21.2%) 0.855
Fungi (n, %) 3 (1.3%) 5 (5%) 8 (2.5%) 0.050
Virus (n, %) 15 (6.7%) 5 (5%) 20 (6.1%) 0.550
MR‑proADM (nmol/L) (median, IQR) 2.68 (3.56) 7.44 (6.84) 3.62 (5.6) <0.001
Lactate (mmol/L) (median, IQR) 2.00 (1.54) 3.60 (5.53) 2.12 (2.28) <0.001
CRP (mg/dl) (median, IQR) 147.8 (193.6) 163.0 (181.9) 155.0 (189) 0.200
PCT (ng/ml) (median, IQR) 2.9 (17.5) 5.8 (36.7) 3.54 (27.5) 0.001
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Mortality rates depending on the source of infection were 
as follows: 37.2% in patients suffering from a respiratory 
infection, 32.4% in those with an urological infection, 
28.6% in patients with an abdominal infection, 35.5% in 
those showing a primary or secondary bacteremia and 
25.6% in those patients with an infection of other ori-
gin. Regarding microbiological identification, both sur-
vivors and non-survivors showed a similar presence of 
Gram−, Gram+ and virus pathogens. Fungal infections 
were more frequent in non-survivors. The most com-
mon cause of death was multi-organ dysfunction syn-
drome (n  =  58; 57.4%), followed by refractory shock 
(n = 9; 8.9%) and refractory hypoxemia (n = 8; 7.9%). A 
limitation of therapeutic effort was applied to 21 patients. 
MR-proADM, PCT and lactate concentrations were all 
significantly elevated in non-surviving patients compared 
to survivors (all p < 0.01), whereas CRP levels remained 
similar in both groups. Levels of MR-proADM depend-
ing on the source of infection were as follows [median 
(interquartile range)] respiratory infection [3.6  nmol/L 
(5.6)], urological infection [4.6  nmol/L (5.4)], abdomi-
nal infection [4.9 nmol/L (6.5)], bacteremia [3.8 nmol/L 
(5.1)], and [3.5  nmol/L (5.8)] in infections of other ori-
gin. Levels of MR-proADM depending on the infect-
ing microbe were [median (interquartile range)]: fungal 
infection [6.1 nmol/L (5.6)], Gram − bacteria [4.9 nmol/L 
(5.9)], Gram  +  bacteria [4.1  nmol/L (6.2)] or viruses 
[1.2 nmol/L (3.4)].
Survival analysis
MR-proADM, PCT and lactate showed a significant 
association with mortality in the univariate Cox regres-
sion analysis (Table  2). After adjusting for confounders 
and compared to PCT, CRP, and lactate, MR-proADM 
showed the strongest independent association with 
the risk of mortality (hazard ratio 8.5; 95% confidence 
interval 4.2–17.4; p  <  0.001; Table  2). In addition, 
Kaplan–Meier analysis showed that no patients with 
a MR-proADM value ≤0.88  nmol/L died in the first 
28 days following ICU admission (Fig. 1). This cut-off was 
selected since it provided a sensitivity of 100% in identi-
fying non-survivors in the AUROC (Fig. 2).
Adjusting variables were: age, septic shock, cardiovas-
cular disease, immunosuppression, chronic renal failure, 
neoplasia, respiratory source of infection, renal replace-
ment therapy, hospital (Valladolid/Dijon), presence of 
fungal infection, limitation of therapeutic effort.
The influence of disease severity on biomarker 
performance
MR-proADM showed the best AUROC for mortal-
ity prediction at 28  days in the analysis over the entire 
cohort, even better than that of SOFA score (Fig.  2). 
When patients were stratified by the degree of organ 
failure, MR-proADM was the only biomarker able to 
discriminate non-survivors from survivors at 28 days in 
those patients with the lowest degree of disease sever-
ity (SOFA score  ≤  6), (AUROC [95% confidence inter-
val (95% CI)] 0.75 [0.61–0.88]), (p  =  0.006) (Fig.  3). In 
the moderately severe patients (SOFA score 7–12), MR-
proADM showed a higher AUROC than that observed 
with lactate (0.74 [0.66–0.83] vs. 0.61 [0.52–0.71], respec-
tively, Fig.  3). In the most severe patients (SOFA score 
≥13), MR-proADM and lactate had a similar AUROC 
(0.73 [0.59–0.86] vs. 0.72 [0.59–0.86], respectively, Fig. 3). 
Neither CRP nor PCT was predictive of 28-day mortal-
ity in any severity group based on the SOFA score, with 
AUROCs ranging from 0.43 to 0.60.
The threshold values (cut-off) of MR-proADM were 
determined by having the highest specificity with a 
pre-fixed sensitivity of at least 0.80 for identifying non-
survivors. For patients with SOFA scores ≤6, 7–12, and 
≥13, the MR-proADM cut-offs were 1.79, 3.25, and 
5.58 nmol/L, respectively (Table 3).
Table 2 Uni- and  multivariate Cox regression analysis 
for  mortality prediction at  28  days following  ICU admis-
sion
Univariate Multivariate
HR (95% CI) p HR (95% CI) p
MR‑proADM 11.2 (6.3–19.8) <0.001 8.5 (4.2–17.4) <0.001
Lactate 3.8 (2.6–5.5) <0.001 3.4 (2.0–5.8) <0.001
CRP 1.3 (0.8–1.9) 0.266 – –
PCT 1.4 (1.2–1.8) 0.001 1.1 (0.9–1.4) 0.326
SOFA 1.2 (1.2–1.3) <0.001 1.2 (1.1–1.3) <0.001 Fig. 1 Kaplan–Meier analysis for mortality prediction at 28 days
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The length of ICU stay in each severity group was 
[mean, (SD)]: SOFA  ≤  6: 11.0  days (18.3); SOFA 7–12: 
12.4 days (16.0) and SOFA ≥ 13: 8.4 days (7.6). The mor-
tality rates for each severity group were 12.8, 30.6 and 
59.7%, respectively.
MR-proADM improves mortality prediction in the less 
severely ill patients
We evaluated the combination of MR-proADM and 
SOFA score in predicting mortality, such that patients 
with MR-proADM concentrations >1.79  nmol/L were 
considered to have a 1 point increase in the SOFA score. 
In patients with SOFA ≤  6, the MR-proADM modified 
SOFA score (ADM-SOFA) showed an increased abil-
ity to identify non-survivors compared to SOFA alone, 
AUROC [95% CI] SOFA 0.70 [0.58–0.82] and ADM-
SOFA 0.77 [0.66–0.88].
Discussion
Severity in sepsis depends on the extent of organ failure 
as evaluated by the SOFA score, which in turn is directly 
associated with the risk of mortality [15]. Nonetheless, 
AUROC [95 %CI] p 
MR-proADM 0.79 [0.74 - 0.84]  < 0.001  
Lactate 0.71 [0.64 - 0.77]  < 0.001  
CRP 0.54 [0.47 - 0.61]  0.248  
PCT 0.61 [0.55 - 0.68]  < 0.001  
SOFA 0.75 [0.69 - 0.80]  < 0.001  




MR-proADM 0.75  [0.61 - 0.88] 0.006 
Lactate 0.62  [0.41 - 0.83] 0.165 
CRP 0.43  [0.23 - 0.62] 0.428 
PCT 0.58  [0.44 - 0.73] 0.341 
SOFA < 6 





0.74             
[0.66 - 0.83] 0.000 
Lactate 
0.61 
 [0.52 - 0.71] 0.018 
CRP 
0.53 
 [0.44 - 0.62] 0.549 
PCT 
0.56  
[0.46 - 0.65] 0.250 
SOFA 7-12 
N= 170 patients 
SOFA > 13 


















[0.44 - 0.73] 
0.279 
Fig. 3 AUROC analysis for identifying non‑survivors at 28 days depending on biomarker levels in the three severity groups
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the emergence of an increasing number of biomarkers 
may provide a new avenue with which to improve prog-
nostic accuracy in a simple and rapid manner. In this 
regard, our study suggests that MR-proADM may be a 
promising biomarker. However, previous studies evalu-
ating the prognostic role of MR-proADM in sepsis have 
provided conflicting results. Christ-Crain et al. [16] found 
that MR-proADM yielded an AUROC of 0.81 for detect-
ing ICU mortality in a group of 53 patients with sepsis. In 
contrast, Suberviola et al. [17] found limited value of MR-
proADM for predicting hospital mortality in 137 sepsis 
patients, with an AUROC of 0.62. Yet Marino et al. [18] 
showed that in 101 patients with sepsis, severe sepsis or 
septic shock, plasma adrenomedullin was strongly asso-
ciated with the severity of disease, vasopressor require-
ment and 28-day mortality. These divergent results on 
the prognostic role of MR-proADM may be explained 
by differences in patient characteristics, disease severity, 
infectious source, surgical versus medical and small sam-
ple sizes across the various studies.
In the present study, we demonstrated for the first time 
that the performance of biomarkers to predict mortality 
in sepsis strongly depends on the degree of organ failure 
upon ICU admission. Stratifying patients based on their 
SOFA score allowed us to demonstrate that MR-proADM 
was the only biomarker able to identify non-survivors in 
all the severity groups. This is particularly important for 
the less severely ill patients (SOFA score ≤ 6), since this 
group represents either the earliest presentation in the 
clinical course of sepsis and/or the less severe form of 
this disease.
Thus, MR-proADM may be a good candidate, after 
validation in further studies, to be incorporated in an 
early sepsis management protocol, since it can pro-
vide rapid prognostic value and help to guide diagnos-
tic interventions and treatment decisions, consequently 
resembling the role of troponin in myocardial infarction 
or d-dimer in pulmonary embolism. The cut-off value 
of MR-proADM identified for this group of patients 
(1.79  nmol/L) could be very useful in this regard. This 
cut-off is able to detect mortality with a good sensitivity 
and a high negative predictive value. Thus, MR-proADM 
may potentially help stratify patients in clinical trials 
examining novel therapies for sepsis.
MR-proADM showed greater predictive value for the 
risk of mortality than other more commonly used bio-
markers, including lactate, in patients with an inter-
mediate degree of organ failure (SOFA score 7–12). 
In contrast, both MR-proADM and lactate performed 
similarly in the most severe patients (SOFA  ≥  13). 
Therefore, our results support the importance of con-
sidering the degree of organ failure when designing 
studies for the discovery of prognostic biomarkers in 
sepsis.
The assessment of organ failure by using the SOFA 
score was recently proposed by the SEPSIS-3 consensus 
to identify high risk patients with suspected infection [15]. 
Our results show that a “positive” MR-proADM value 
may improve the ability of SOFA to predict mortality in 
sepsis. Interestingly, a combination of MR-proADM with 
clinical scores such as PSI or CURB-65 also performed 
better than the clinical scores alone in patients with Com-
munity Acquired Pneumonia (CAP) or lower respiratory 
tract infections (LRTI) [12, 19–21]. As a result, MR-
proADM could be used as a reliable risk-stratification tool 
with the ability to predict mortality or adverse events and 
to guide clinical decisions. Further clinical studies evalu-
ating strategies combining MR-proADM with other clas-
sical severity scores and/or biomarkers for improving the 
recognition and prognostication of sepsis are therefore 
warranted [22, 23].
Finally, we observed that an MR-proADM value lower 
than 0.88 nmol/L may allow to “rule out” mortality in the 
28 days following admission to the ICU. This cut-off may 
be especially useful for guiding early clinical decisions, 
when the clinical signs of overt organ failure are not yet 
apparent.
Indeed, our results are similar to those of previous 
studies. Albrich et  al. found that patients with LRTI 
and MR-proADM concentrations <0.75  nmol/L had an 
overall mortality of less than 0.5% (11). Furthermore, 
Krüger et al. showed that patients with CAP and an MR-
proADM concentration of <0.9  nmol/L had a survival 
probability of 99.3% (12). Bello et  al. [24] also found an 
optimal MR-proADM cut-off for predicting 30-day mor-
tality in patients with CAP of 1.06 nmol/L.
Our study is limited in that we evaluated MR-proADM 
and other biomarker levels only on the day of ICU 
Table 3 MR-proADM cut-off (nmol/L) with the highest accuracy for predicting 28-day mortality based on SOFA score
PPV positive predictive value, NPV negative predictive value, +LR positive likelihood ratio, −LR negative likelihood ratio
Cut-off Sensitivity Specificity PPV NPV +LR −LR
SOFA < 6 1.79 83.0 61.0 23.8 96.2 2.14 0.27
SOFA 7–12 3.25 83.0 52.0 43.4 87.0 1.74 0.33
SOFA ≥ 13 5.58 83.8 60.0 75.6 71.4 2.09 0.27
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admission. As a result, we cannot extrapolate our find-
ings to the emergency department or general ward. MR-
proADM monitoring over time may further illustrate a 
temporal trend, which can indicate the success of specific 
therapies and consequently increase its outcome pre-
dictive value [25]. Finally, in our cohort, MR-proADM 
levels slightly differed depending on the source of infec-
tion. Fungal infections induced the highest levels of 
MR-proADM, while viral infection induced the lowest. 
This was likely related to the fact that fungal infections 
resulted in a higher disease severity (median SOFA score 
of 12 vs. 9 points in patients with no fungal infection), 
while viral infections resulted in a milder disease severity 
(median SOFA score of 6.5 vs. 9 points in patients with 
no viral infection). The potential influence of the source 
of infection and the type of microbe on MR-proADM’s 
ability to predict mortality in sepsis merits further 
investigation.
Conclusions
Our results demonstrate that the performance of bio-
markers in determining the risk of mortality in sepsis is 
influenced by disease severity. In patients with moder-
ate severity, MR-proADM outperformed other standard 
biomarkers. As a consequence, MR-proADM may aid 
the early identification of sepsis patients requiring urgent 
ICU admission as well as facilitating the subsequent clin-
ical management of these patients.
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